Pipeline
Pushing boundaries in cancer vaccine development
We are developing next-generation vaccines, immunomodulators, and adjuvants that leverage our lymph node–targeting Amphiphile (AMP) platform, engineered to defeat the most challenging cancers.
As we make strides in advancing our existing candidates, we aspire to extend our reach to address other therapeutic indications that can leverage the potent and flexible capabilities of our AMP platform.
We are actively seeking partnerships and licensing opportunities to fully leverage the therapeutic potential of our platform, and to explore a broader set of indications.
Candidate
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
ELI-002
mKRAS
PDAC, CRC
Preclinical
Phase 1
Phase 2
Phase 3
ELI-007
mBRAF
GI tumors
Preclinical
Phase 1
Phase 2
Phase 3
ELI-008
mTP53
GI tumors
Preclinical
Phase 1
Phase 2
Phase 3
CRC: colorectal carcinoma | PDAC: pancreatic ductal adenocarcinoma
mKRAS: mutant Kirsten rat sarcoma | mBRAF: mutant homolog B of the Rapidly Accelerated Fibrosarcoma | mTP53: mutant tumor protein p53
Our lead candidate, ELI-002, is a lymph node–targeted mutant Kristen rat sarcoma (mKRAS) cancer vaccine. Built with our AMP platform, ELI-002 is designed to target the most common KRAS mutations that drive 25% of all solid tumors.
Our preclinical programs demonstrate the broad therapeutic potential of our AMP platform to treat challenging cancers, including mBRAF and mTP53-driven cancers.